MARKETS

S&P 500 7,376.86 +0.31% NASDAQ 24,579.42 +1.09% FTSE 100 10,673.94 -1.01% NIKKEI 57,435 -5.96% BRENT $98.32 +0.03% GOLD $4,074.9 -0.94%

Delayed 15 min · 19:00 GMT

FLASH

Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump Panama’s $8.5B Bet: The Canal That Wants to Be More Than a Canal Microsoft reportedly winds down Oracle AI-computing deal; Oracle falls 4% Up 1,500, down 1,800: Wall Street’s wildest week since the 2025 tariff crash Fox closes $22B Roku takeover months ahead of schedule Nikkei, Kospi plunge 6% as AI crash spreads to Asia Nasdaq crashes 5.5% as $2.5 trillion vanishes in AI rout Europe’s Stoxx 600 hits record as money rotates out of AI Toyota soars 16.7%, raises profit forecast 15% on hybrids, weak yen Europe’s defence darling, Rheinmetall, plunges 16% after second sales cut in three months

Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump Panama’s $8.5B Bet: The Canal That Wants to Be More Than a Canal Microsoft reportedly winds down Oracle AI-computing deal; Oracle falls 4% Up 1,500, down 1,800: Wall Street’s wildest week since the 2025 tariff crash Fox closes $22B Roku takeover months ahead of schedule Nikkei, Kospi plunge 6% as AI crash spreads to Asia Nasdaq crashes 5.5% as $2.5 trillion vanishes in AI rout Europe’s Stoxx 600 hits record as money rotates out of AI Toyota soars 16.7%, raises profit forecast 15% on hybrids, weak yen Europe’s defence darling, Rheinmetall, plunges 16% after second sales cut in three months

Industries

Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump

Moderna more than doubled its revenue growth guidance, helped by a new flu vaccine approval and positive cancer-vaccine data. It’s a sign the business is moving beyond COVID.

News | 7 November 2026

Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump

Moderna’s third-quarter revenue rose 29% to $1.313 billion, up from $1.016 billion a year earlier.

It swung to a net profit of $162 million, against a loss of $200 million in Q3 2025. Diluted EPS was $0.38, compared with a $0.51 loss.

US sales were $780 million and international sales $533 million.

The company now expects 2026 revenue to grow 15%–25%, up from its earlier forecast of up to 10%.

It also cut its R&D budget to about $2.7 billion from about $2.9 billion, and raised its year-end cash forecast to $8.1–8.3 billion from $4.7–5.2 billion.

Two milestones help diversify the business beyond COVID: US approval of the mFLUSIVA flu vaccine and positive Phase 3 results for the intismeran cancer vaccine in melanoma.